Lumexa Imaging Holdings, Inc. (LMRI) Guidance & Earnings Results

On 2026-08-12 Lumexa Imaging Holdings, Inc. mixed guidance: "FY26 revenue reiterated $1.045B-$1.097B; FY26 Adjusted EBITDA narrowed to $235M-$241M from $234M-$242M (midpoint unchanged at $238M); FY26 Adjusted EPS reiterated…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · read by EquiReason

LMRILumexa Imaging Holdings, Inc.Follow LMRI — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 1.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 12 Nov, in 19 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
12 Aug 26	Mixed	FY26 revenue reiterated $1.045B-$1.097B; FY26 Adjusted EBITDA narrowed to $235M-$241M from $234M-$242M (midpoint unchanged at $238M); FY26 Adjusted EPS reiterated $0.71-$0.77 · full year
12 May 26	Reaffirmed	FY26 consolidated revenues $1.045-1.097B; FY26 adjusted EBITDA $234-242M (includes ~$7M public company costs); FY26 adjusted EPS $0.71-0.77 · full year
26 Mar 26	Reaffirmed	FY2026 revenue $1.045-1.097B; Adj EBITDA $234-242M; Adj EPS $0.71-0.77 · full year
2 Mar 26	Raised	FY2026 consolidated revenue $1.045-1.097B; Adjusted EBITDA $234-242M (incl. ~$7M public company costs) · full year

Lumexa Imaging Holdings, Inc. — questions

What guidance did Lumexa Imaging Holdings, Inc. give?: On 2026-08-12: "FY26 revenue reiterated $1.045B-$1.097B; FY26 Adjusted EBITDA narrowed to $235M-$241M from $234M-$242M (midpoint unchanged at $238M); FY26 Adjusted EPS reiterated $0.71-$0.77"
When does Lumexa Imaging Holdings, Inc. report earnings?: Lumexa Imaging Holdings, Inc.'s next earnings report is expected on 2026-11-12.

Every figure on this page comes from Lumexa Imaging Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.